Valeant Announces 2017 Annual Meeting Results

LAVAL, Quebec, May 3, 2017 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) ("Valeant" or the "Company") announced today the election of the ten directors nominated at its 2017 annual meeting of shareholders held on May 2, 2017. The detailed results of the vote for the election of directors are set out below:

Name		For		Withheld		Broker Non-Votes
Richard U. DeSchutter		123,623,109		5,319,736		98,872,954
Dr. Frederic N. Eshelman		126,125,069		2,817,776		98,872,954
D. Robert Hale		123,127,211		5,815,634		98,872,954
Dr. Argeris (Jerry) N. Karabelas		123,529,948		5,412,897		98,872,954
Sarah B. Kavanagh		126,292,442		2,650,403		98,872,954
Joseph C. Papa		123,983,101		4,959,744		98,872,954
Robert N. Power		125,649,938		3,292,907		98,872,954
Russel C. Robertson		126,590,227		2,352,618		98,872,954
Thomas W. Ross, Sr.		126,166,299		2,776,546		98,872,954
Amy B. Wechsler, M.D.		123,473,243		5,469,602		98,872,954

At the annual meeting, shareholders also approved the non-binding advisory vote on named executive officer compensation and an annual frequency of advisory votes on the compensation of our named executive as disclosed in the proxy statement and appointed PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm until the close of the Company's 2018 annual meeting of shareholders.

The final vote tabulation on all matters voted on at the meeting will be reported to the U.S. Securities and Exchange Commission on a current report on Form 8-K and such report will be made available on the Company's web site at www.valeant.com.

About Valeant
Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com.

Contact Information:

Elif McDonald
[e-mail]         
514-856-3855
877-281-6642 (toll free)

Media:
Renée Soto
or
Chris Kittredge/Jared Levy
Sard Verbinnen & Co.
212-687-8080

 

SOURCE Valeant Pharmaceuticals International, Inc.

Copyright 2017 Canada NewsWire